Cargando…

Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial

In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,00...

Descripción completa

Detalles Bibliográficos
Autores principales: Obi, Yoshitsugu, Yamaguchi, Satoshi, Hamano, Takayuki, Sakaguchi, Yusuke, Shimomura, Akihiro, Namba-Hamano, Tomoko, Mikami, Satoshi, Nishi, Osamu, Tanaka, Motoko, Kamoto, Akihito, Obi, Yasue, Tomosugi, Naohisa, Tsubakihara, Yoshiharu, Isaka, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512011/
https://www.ncbi.nlm.nih.gov/pubmed/32968158
http://dx.doi.org/10.1038/s41598-020-72385-w
_version_ 1783586070820028416
author Obi, Yoshitsugu
Yamaguchi, Satoshi
Hamano, Takayuki
Sakaguchi, Yusuke
Shimomura, Akihiro
Namba-Hamano, Tomoko
Mikami, Satoshi
Nishi, Osamu
Tanaka, Motoko
Kamoto, Akihito
Obi, Yasue
Tomosugi, Naohisa
Tsubakihara, Yoshiharu
Isaka, Yoshitaka
author_facet Obi, Yoshitsugu
Yamaguchi, Satoshi
Hamano, Takayuki
Sakaguchi, Yusuke
Shimomura, Akihiro
Namba-Hamano, Tomoko
Mikami, Satoshi
Nishi, Osamu
Tanaka, Motoko
Kamoto, Akihito
Obi, Yasue
Tomosugi, Naohisa
Tsubakihara, Yoshiharu
Isaka, Yoshitaka
author_sort Obi, Yoshitsugu
collection PubMed
description In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thrice-weekly placebo, or (4) once-monthly placebo. We also examined the effect modifications by selected single nucleotide polymorphisms in vitamin D-related genes. Out of 96 participants, 94 were available at Month 3, and 88 completed the 6-month study. After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance. Cholecalciferol increased serum 1,25(OH)(2)D levels, resulting in a greater proportion of patients who reduced the dose of active vitamin D at Month 6 (31% vs. 10% in the placebo group). Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency. In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients. Both thrice-weekly and once-monthly supplementation effectively increases serum 1,25(OH)(2)D levels, and hence, reduces active vitamin D drugs. Clinical Trial Registry: This study was registered at ClinicalTrials.gov and University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as NCT02214563 (registration date: 12/08/2014) and UMIN000011786 (registration date: 15/08/2014), respectively (please refer to the links below). ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT02214563. UMIN-CTR: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000017152&language=E.
format Online
Article
Text
id pubmed-7512011
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75120112020-09-29 Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial Obi, Yoshitsugu Yamaguchi, Satoshi Hamano, Takayuki Sakaguchi, Yusuke Shimomura, Akihiro Namba-Hamano, Tomoko Mikami, Satoshi Nishi, Osamu Tanaka, Motoko Kamoto, Akihito Obi, Yasue Tomosugi, Naohisa Tsubakihara, Yoshiharu Isaka, Yoshitaka Sci Rep Article In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients. Participants were assigned in a 2:2:1:1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thrice-weekly placebo, or (4) once-monthly placebo. We also examined the effect modifications by selected single nucleotide polymorphisms in vitamin D-related genes. Out of 96 participants, 94 were available at Month 3, and 88 completed the 6-month study. After adjustment for baseline values, serum hepcidin levels were higher at Day 3 in the combined cholecalciferol (vs. placebo) group, but were lower at Month 6 with increased erythropoietin resistance. Cholecalciferol increased serum 1,25(OH)(2)D levels, resulting in a greater proportion of patients who reduced the dose of active vitamin D at Month 6 (31% vs. 10% in the placebo group). Cholecalciferol also suppressed intact PTH only among patients with severe vitamin D deficiency. In conclusion, cholecalciferol supplementation increases serum hepcidin-25 levels in the short term and may increase erythropoietin resistance in the long term among haemodialysis patients. Both thrice-weekly and once-monthly supplementation effectively increases serum 1,25(OH)(2)D levels, and hence, reduces active vitamin D drugs. Clinical Trial Registry: This study was registered at ClinicalTrials.gov and University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as NCT02214563 (registration date: 12/08/2014) and UMIN000011786 (registration date: 15/08/2014), respectively (please refer to the links below). ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/record/NCT02214563. UMIN-CTR: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000017152&language=E. Nature Publishing Group UK 2020-09-23 /pmc/articles/PMC7512011/ /pubmed/32968158 http://dx.doi.org/10.1038/s41598-020-72385-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Obi, Yoshitsugu
Yamaguchi, Satoshi
Hamano, Takayuki
Sakaguchi, Yusuke
Shimomura, Akihiro
Namba-Hamano, Tomoko
Mikami, Satoshi
Nishi, Osamu
Tanaka, Motoko
Kamoto, Akihito
Obi, Yasue
Tomosugi, Naohisa
Tsubakihara, Yoshiharu
Isaka, Yoshitaka
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title_full Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title_fullStr Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title_full_unstemmed Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title_short Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
title_sort effect of cholecalciferol on serum hepcidin and parameters of anaemia and ckd-mbd among haemodialysis patients: a randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512011/
https://www.ncbi.nlm.nih.gov/pubmed/32968158
http://dx.doi.org/10.1038/s41598-020-72385-w
work_keys_str_mv AT obiyoshitsugu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT yamaguchisatoshi effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT hamanotakayuki effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT sakaguchiyusuke effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT shimomuraakihiro effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT nambahamanotomoko effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT mikamisatoshi effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT nishiosamu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT tanakamotoko effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT kamotoakihito effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT obiyasue effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT tomosuginaohisa effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT tsubakiharayoshiharu effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial
AT isakayoshitaka effectofcholecalciferolonserumhepcidinandparametersofanaemiaandckdmbdamonghaemodialysispatientsarandomizedclinicaltrial